Prospective Risk Evaluation and Detection of Crohn's Disease in First-degree Relatives
PREDICT-CD
1 other identifier
observational
10,000
6 countries
10
Brief Summary
The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease. This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland. To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions. At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2026
Typical duration for all trials
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 5, 2025
CompletedFirst Posted
Study publicly available on registry
January 5, 2026
CompletedStudy Start
First participant enrolled
April 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2029
July 29, 2026
July 1, 2026
3.8 years
December 5, 2025
July 27, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Development of Crohn's disease during the study period
Diagnosis confirmed according to established diagnostic criteria, specifically endoscopy and histopathology
From enrolment until end of study follow-up (up to 3 years)
Secondary Outcomes (4)
Proportion of first-degree relatives classified as high risk according to the PREDICT-CD risk prediction algorithm
From enrolment until end of study follow-up (up to 3 years)
Clinical and lifestyle characteristics of high-risk individuals who develop inflammatory bowel disease
From enrolment until end of study follow-up (up to 3 years)
Incidence of newly diagnosed immune-mediated inflammatory diseases other than Crohn's disease
From enrolment until end of study follow-up (up to 3 years)
Participant-reported willingness to receive predictive risk information and participate in preventive interventions
From enrolment until end of study follow-up (up to 3 years)
Study Arms (1)
First-degree relatives
Eligibility Criteria
The first-degree relative without a previous diagnosis of Inflammatory Bowel Disease
You may qualify if:
- Male or female participants, between 16 and 35 years old
- FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
- Participants able to understand the information provided to them and to give written informed assent or consent for the study.
You may not qualify if:
- Prior diagnosis of IBD
- Any legal or medical condition that limits the information and participation in the study
- Inability to verify CD diagnosis in the proband
- Participants unwilling or unable to provide informed written consent
- Participants unwilling or unable to donate blood for serum
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
AUMC
Amsterdam, Netherlands
UMCG
Groningen, Netherlands
Państwowy Instytut Medyczny MSWiA w Warszawie
Warsaw, Poland
Hospital Beatriz Ângelo
Lisbon, Portugal
Hospital da Luz Lisboa
Lisbon, Portugal
Hospital dos Capuchos
Lisbon, Portugal
Hospital Santa Maria
Lisbon, Portugal
Hospital Galdakao-Usansolo
Galdakao, Spain
Örebro University Hospital
Örebro, Sweden
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 5, 2025
First Posted
January 5, 2026
Study Start
April 1, 2026
Primary Completion (Estimated)
December 31, 2029
Study Completion (Estimated)
December 31, 2029
Last Updated
July 29, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share